ENTITY

Sonnet BioTherapeutics Holding (SONN US)

Health Care • United States

Sonnet BioTherapeutics Holdings, Inc. operates as a clinical stage biotechnology company. The Company develops fully human albumin binding technology that helps the development of innovative targeted biologic drugs with enhanced single-or bi-specific mechanisms. Sonnet BioTherapeutics Holdings serves customers in the United States.

Refresh

No presentations found

We’ll display presentations we find for Sonnet BioTherapeutics Holding here

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00